Matregen is a private company focused on the development and commercialization of novel Drug Delivery Systems, creating high value products for pharmaceutical companies in the chronic and palliative care markets. Matregen Corp was established in 2002 as a biomaterials company, leveraging the cutting-edge research and IP generated from Prof. Molly Shoichet’s lab at the Institute of Biomaterials & Biomedical Engineering, University of Toronto.